The market is segmented based on Global Needle-Free Drug Delivery Market Segmentation, By Product (Prefilled Needle-Free Injection Systems and Fillable Needle-Free Injection Systems), Technology (Inhaler, Novel Needle-Free, Jet Injector and Transdermal Patch), Application (Insulin Delivery, Vaccination, Pediatric Injections, and Pain Management), Injection Method (Powder injections, Liquid injections, and Depot or Projectile Injection), Source of Power (Spring Load Jet Injector Systems, Gas Powdered Jet Injector, and Battery Powdered Jet Injector System) – Industry Trends and Forecast to 2031
.
The Global Needle Free Drug Delivery Market size was valued at USD 13.09 USD Billion in 2023.
The Global Needle Free Drug Delivery Market is projected to grow at a CAGR of 9.95% during the forecast period of 2024 to 2031.
The major players operating in the market include Antares Pharmed , Tianjin Xuying Technology Development Co. , Verdict Media Limited, 3M PharmaJet, Zogenix, Inovio Pharmaceuticals , Valeritas , Akra Dermo-Jet, D'Antonio Consultants International , Endo Pharmaceuticals , BD, CROSSJECT MIT Canada, MedImmune, Mystic Pharmaceuticals, Needle Free Injection System, Inolife Sciences, Ferring B.V., OptiNose US , Pfizer -.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.